Cargando…

Drug-Induced Interstitial Lung Disease after Anthracycline-Combined Chemotherapy for Breast Cancer: A Case Report and Literature Review

Drug-induced interstitial lung disease (DILD) has been occasionally reported with various causative drugs. In the context of breast cancer, anthracycline infrequently causes pulmonary adverse events. We report a 67-year-old woman with cT2N0M0 triple-negative breast cancer who received neoadjuvant ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoshina, Hideko, Takei, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740208/ https://www.ncbi.nlm.nih.gov/pubmed/35082624 http://dx.doi.org/10.1159/000520126

Ejemplares similares

Radiation-induced fibrosarcoma after breast-conserving therapy for breast cancer: a case report and literature review
por: Hoshina, Hideko, et al.
Publicado: (2023)

Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature
por: Hoshina, Hideko, et al.
Publicado: (2019)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: A case report
por: Zhao, Xiangwang, et al.
Publicado: (2023)

Mitral regurgitation after anthracycline-based chemotherapy in an adult patient with breast cancer: A case report
por: Liu, Xiaoyan, et al.
Publicado: (2017)

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen
por: Dong, Zhaoying, et al.
Publicado: (2021)

Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment
por: Cai, Fengfeng, et al.
Publicado: (2019)

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment
por: Abdel-Fatah, Tarek M. A., et al.
Publicado: (2019)

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
por: Hackshaw, A, et al.
Publicado: (2005)

Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients
por: Frères, Pierre, et al.
Publicado: (2018)

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
por: Beaudry, Rhys I., et al.
Publicado: (2019)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

Anthracycline-induced cardiotoxicity: A case report and review of literature
por: Chong, Esther G, et al.
Publicado: (2021)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine
por: Tanabe, Masahiko
Publicado: (2016)

Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer
por: Boekel, Naomi B., et al.
Publicado: (2018)

Case report: Evaluation of myocardial microcirculation in patients with breast cancer after anthracycline chemotherapy by using intravoxel incoherent motion imaging
por: Li, Shilan, et al.
Publicado: (2022)

Long QT syndrome and torsade de pointes after anthracycline chemotherapy
por: Colombo, N, et al.
Publicado: (2009)

Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer
por: Mulligan, Jude M., et al.
Publicado: (2014)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Process analysis of anthracycline adverse reactions in breast cancer patients with postoperative chemotherapy
por: Liu, Chang, et al.
Publicado: (2022)

Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer
por: Wang, Yuehan, et al.
Publicado: (2023)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

The Development and Testing of a Chemotherapy-Induced Phlebitis Severity (CIPS) Scale for Patients Receiving Anthracycline Chemotherapy for Breast Cancer
por: Harris, Valerie, et al.
Publicado: (2020)

Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma
por: Fujiwara, Kazuko, et al.
Publicado: (2011)

Drug-Induced Interstitial Pneumonia due to Application of FOLFOX as Adjuvant Chemotherapy after Rectal Cancer Surgery: A Case Report and Literature Review
por: Yanagawa, Senichiro, et al.
Publicado: (2020)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population
por: Tan, Varen Zhi Zheng, et al.
Publicado: (2021)

Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer()()
por: Tibau, Ariadna, et al.
Publicado: (2014)

Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
por: Mina, Alain, et al.
Publicado: (2015)

Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
por: Boczar, Kevin Emery, et al.
Publicado: (2016)

FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
por: Xing, Mingyou, et al.
Publicado: (2019)

Effect of Eplerenone on Diastolic Function in Women Receiving Anthracycline-Based Chemotherapy for Breast Cancer
por: Davis, Margot K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kbtb6lmmjbgbtf2r5s6914fve1